A Chinese inactivated vaccine shows 79.34 per cent efficiency against Coronvairus, according to the interim results of phase three clinical trials unveiled by its developer on Wednesday.
The inactivated vaccine has been developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliated to Sinopharm.
After a two-dose vaccination procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralising antibodies reached 99.52 per cent.
The results meet the requirements of technical standards of the World Health Organization and the standards stipulated by China's National Medical Products Administration (NMPA).
The company has submitted an application to the Chinese regulator for conditional market approval.